The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Anti-CD133 Antibody Market Research Report 2025

Global Anti-CD133 Antibody Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1897604

No of Pages : 108

Ask Your Query
Synopsis
Anti-CD133 Antibody is an antibody that specifically binds to CD133, a cell surface protein known as cluster of differentiation 133. CD133 is primarily found on stem cells, including those of the blood and epithelial tissues. This antibody is widely used in research to isolate and study stem cells, particularly in the context of cancer research, where CD133 has been associated with tumor initiating cells. It is also explored for its potential in regenerative medicine and tissue engineering due to CD133's presence on cells with regenerative potential.
The global Anti-CD133 Antibody market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The industry trend for Anti-CD133 Antibody has seen a rise as it becomes an increasingly important tool in stem cell research and oncology. The antibody's role in identifying and isolating cancer stem cells has implications for the development of novel therapeutics targeting these cells, which are believed to be responsible for tumor recurrence and resistance to treatment. Additionally, the potential for CD133 in regenerative applications is driving the demand for high-quality Anti-CD133 Antibody products. As research progresses and the functions of CD133 in various diseases are further understood, the industry trend for this antibody is expected to continue growing.
This report aims to provide a comprehensive presentation of the global market for Anti-CD133 Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-CD133 Antibody.
Report Scope
The Anti-CD133 Antibody market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-CD133 Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-CD133 Antibody companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BosterBio
GeneTex
ProSci
Bioss
Absolute Antibody
MyBioSource
Biorbyt
Thermo Fisher Scientific
R&D Systems
Novus Biologicals
BioLegend
G Biosciences
Cell Signaling Technology
RayBiotech
HUABIO
Abeomics
Proteintech Group
Miltenyi Biotec
Wuhan Fine Biotech
NSJ Bioreagents
Bethyl Laboratories
OriGene Technologies
Signalway Antibody
Abnova
Bioassay Technology Laboratory
AAT Bioquest
Sino Biological
ProteoGenix
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Biotechnology
Medical
University
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-CD133 Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-CD133 Antibody Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global Anti-CD133 Antibody Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-CD133 Antibody Market Perspective (2019-2030)
2.2 Anti-CD133 Antibody Growth Trends by Region
2.2.1 Global Anti-CD133 Antibody Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-CD133 Antibody Historic Market Size by Region (2019-2024)
2.2.3 Anti-CD133 Antibody Forecasted Market Size by Region (2025-2030)
2.3 Anti-CD133 Antibody Market Dynamics
2.3.1 Anti-CD133 Antibody Industry Trends
2.3.2 Anti-CD133 Antibody Market Drivers
2.3.3 Anti-CD133 Antibody Market Challenges
2.3.4 Anti-CD133 Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-CD133 Antibody Players by Revenue
3.1.1 Global Top Anti-CD133 Antibody Players by Revenue (2019-2024)
3.1.2 Global Anti-CD133 Antibody Revenue Market Share by Players (2019-2024)
3.2 Global Anti-CD133 Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-CD133 Antibody Revenue
3.4 Global Anti-CD133 Antibody Market Concentration Ratio
3.4.1 Global Anti-CD133 Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-CD133 Antibody Revenue in 2023
3.5 Anti-CD133 Antibody Key Players Head office and Area Served
3.6 Key Players Anti-CD133 Antibody Product Solution and Service
3.7 Date of Enter into Anti-CD133 Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-CD133 Antibody Breakdown Data by Type
4.1 Global Anti-CD133 Antibody Historic Market Size by Type (2019-2024)
4.2 Global Anti-CD133 Antibody Forecasted Market Size by Type (2025-2030)
5 Anti-CD133 Antibody Breakdown Data by Application
5.1 Global Anti-CD133 Antibody Historic Market Size by Application (2019-2024)
5.2 Global Anti-CD133 Antibody Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-CD133 Antibody Market Size (2019-2030)
6.2 North America Anti-CD133 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-CD133 Antibody Market Size by Country (2019-2024)
6.4 North America Anti-CD133 Antibody Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-CD133 Antibody Market Size (2019-2030)
7.2 Europe Anti-CD133 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-CD133 Antibody Market Size by Country (2019-2024)
7.4 Europe Anti-CD133 Antibody Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-CD133 Antibody Market Size (2019-2030)
8.2 Asia-Pacific Anti-CD133 Antibody Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-CD133 Antibody Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-CD133 Antibody Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-CD133 Antibody Market Size (2019-2030)
9.2 Latin America Anti-CD133 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-CD133 Antibody Market Size by Country (2019-2024)
9.4 Latin America Anti-CD133 Antibody Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-CD133 Antibody Market Size (2019-2030)
10.2 Middle East & Africa Anti-CD133 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-CD133 Antibody Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-CD133 Antibody Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BosterBio
11.1.1 BosterBio Company Detail
11.1.2 BosterBio Business Overview
11.1.3 BosterBio Anti-CD133 Antibody Introduction
11.1.4 BosterBio Revenue in Anti-CD133 Antibody Business (2019-2024)
11.1.5 BosterBio Recent Development
11.2 GeneTex
11.2.1 GeneTex Company Detail
11.2.2 GeneTex Business Overview
11.2.3 GeneTex Anti-CD133 Antibody Introduction
11.2.4 GeneTex Revenue in Anti-CD133 Antibody Business (2019-2024)
11.2.5 GeneTex Recent Development
11.3 ProSci
11.3.1 ProSci Company Detail
11.3.2 ProSci Business Overview
11.3.3 ProSci Anti-CD133 Antibody Introduction
11.3.4 ProSci Revenue in Anti-CD133 Antibody Business (2019-2024)
11.3.5 ProSci Recent Development
11.4 Bioss
11.4.1 Bioss Company Detail
11.4.2 Bioss Business Overview
11.4.3 Bioss Anti-CD133 Antibody Introduction
11.4.4 Bioss Revenue in Anti-CD133 Antibody Business (2019-2024)
11.4.5 Bioss Recent Development
11.5 Absolute Antibody
11.5.1 Absolute Antibody Company Detail
11.5.2 Absolute Antibody Business Overview
11.5.3 Absolute Antibody Anti-CD133 Antibody Introduction
11.5.4 Absolute Antibody Revenue in Anti-CD133 Antibody Business (2019-2024)
11.5.5 Absolute Antibody Recent Development
11.6 MyBioSource
11.6.1 MyBioSource Company Detail
11.6.2 MyBioSource Business Overview
11.6.3 MyBioSource Anti-CD133 Antibody Introduction
11.6.4 MyBioSource Revenue in Anti-CD133 Antibody Business (2019-2024)
11.6.5 MyBioSource Recent Development
11.7 Biorbyt
11.7.1 Biorbyt Company Detail
11.7.2 Biorbyt Business Overview
11.7.3 Biorbyt Anti-CD133 Antibody Introduction
11.7.4 Biorbyt Revenue in Anti-CD133 Antibody Business (2019-2024)
11.7.5 Biorbyt Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Anti-CD133 Antibody Introduction
11.8.4 Thermo Fisher Scientific Revenue in Anti-CD133 Antibody Business (2019-2024)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 R&D Systems
11.9.1 R&D Systems Company Detail
11.9.2 R&D Systems Business Overview
11.9.3 R&D Systems Anti-CD133 Antibody Introduction
11.9.4 R&D Systems Revenue in Anti-CD133 Antibody Business (2019-2024)
11.9.5 R&D Systems Recent Development
11.10 Novus Biologicals
11.10.1 Novus Biologicals Company Detail
11.10.2 Novus Biologicals Business Overview
11.10.3 Novus Biologicals Anti-CD133 Antibody Introduction
11.10.4 Novus Biologicals Revenue in Anti-CD133 Antibody Business (2019-2024)
11.10.5 Novus Biologicals Recent Development
11.11 BioLegend
11.11.1 BioLegend Company Detail
11.11.2 BioLegend Business Overview
11.11.3 BioLegend Anti-CD133 Antibody Introduction
11.11.4 BioLegend Revenue in Anti-CD133 Antibody Business (2019-2024)
11.11.5 BioLegend Recent Development
11.12 G Biosciences
11.12.1 G Biosciences Company Detail
11.12.2 G Biosciences Business Overview
11.12.3 G Biosciences Anti-CD133 Antibody Introduction
11.12.4 G Biosciences Revenue in Anti-CD133 Antibody Business (2019-2024)
11.12.5 G Biosciences Recent Development
11.13 Cell Signaling Technology
11.13.1 Cell Signaling Technology Company Detail
11.13.2 Cell Signaling Technology Business Overview
11.13.3 Cell Signaling Technology Anti-CD133 Antibody Introduction
11.13.4 Cell Signaling Technology Revenue in Anti-CD133 Antibody Business (2019-2024)
11.13.5 Cell Signaling Technology Recent Development
11.14 RayBiotech
11.14.1 RayBiotech Company Detail
11.14.2 RayBiotech Business Overview
11.14.3 RayBiotech Anti-CD133 Antibody Introduction
11.14.4 RayBiotech Revenue in Anti-CD133 Antibody Business (2019-2024)
11.14.5 RayBiotech Recent Development
11.15 HUABIO
11.15.1 HUABIO Company Detail
11.15.2 HUABIO Business Overview
11.15.3 HUABIO Anti-CD133 Antibody Introduction
11.15.4 HUABIO Revenue in Anti-CD133 Antibody Business (2019-2024)
11.15.5 HUABIO Recent Development
11.16 Abeomics
11.16.1 Abeomics Company Detail
11.16.2 Abeomics Business Overview
11.16.3 Abeomics Anti-CD133 Antibody Introduction
11.16.4 Abeomics Revenue in Anti-CD133 Antibody Business (2019-2024)
11.16.5 Abeomics Recent Development
11.17 Proteintech Group
11.17.1 Proteintech Group Company Detail
11.17.2 Proteintech Group Business Overview
11.17.3 Proteintech Group Anti-CD133 Antibody Introduction
11.17.4 Proteintech Group Revenue in Anti-CD133 Antibody Business (2019-2024)
11.17.5 Proteintech Group Recent Development
11.18 Miltenyi Biotec
11.18.1 Miltenyi Biotec Company Detail
11.18.2 Miltenyi Biotec Business Overview
11.18.3 Miltenyi Biotec Anti-CD133 Antibody Introduction
11.18.4 Miltenyi Biotec Revenue in Anti-CD133 Antibody Business (2019-2024)
11.18.5 Miltenyi Biotec Recent Development
11.19 Wuhan Fine Biotech
11.19.1 Wuhan Fine Biotech Company Detail
11.19.2 Wuhan Fine Biotech Business Overview
11.19.3 Wuhan Fine Biotech Anti-CD133 Antibody Introduction
11.19.4 Wuhan Fine Biotech Revenue in Anti-CD133 Antibody Business (2019-2024)
11.19.5 Wuhan Fine Biotech Recent Development
11.20 NSJ Bioreagents
11.20.1 NSJ Bioreagents Company Detail
11.20.2 NSJ Bioreagents Business Overview
11.20.3 NSJ Bioreagents Anti-CD133 Antibody Introduction
11.20.4 NSJ Bioreagents Revenue in Anti-CD133 Antibody Business (2019-2024)
11.20.5 NSJ Bioreagents Recent Development
11.21 Bethyl Laboratories
11.21.1 Bethyl Laboratories Company Detail
11.21.2 Bethyl Laboratories Business Overview
11.21.3 Bethyl Laboratories Anti-CD133 Antibody Introduction
11.21.4 Bethyl Laboratories Revenue in Anti-CD133 Antibody Business (2019-2024)
11.21.5 Bethyl Laboratories Recent Development
11.22 OriGene Technologies
11.22.1 OriGene Technologies Company Detail
11.22.2 OriGene Technologies Business Overview
11.22.3 OriGene Technologies Anti-CD133 Antibody Introduction
11.22.4 OriGene Technologies Revenue in Anti-CD133 Antibody Business (2019-2024)
11.22.5 OriGene Technologies Recent Development
11.23 Signalway Antibody
11.23.1 Signalway Antibody Company Detail
11.23.2 Signalway Antibody Business Overview
11.23.3 Signalway Antibody Anti-CD133 Antibody Introduction
11.23.4 Signalway Antibody Revenue in Anti-CD133 Antibody Business (2019-2024)
11.23.5 Signalway Antibody Recent Development
11.24 Abnova
11.24.1 Abnova Company Detail
11.24.2 Abnova Business Overview
11.24.3 Abnova Anti-CD133 Antibody Introduction
11.24.4 Abnova Revenue in Anti-CD133 Antibody Business (2019-2024)
11.24.5 Abnova Recent Development
11.25 Bioassay Technology Laboratory
11.25.1 Bioassay Technology Laboratory Company Detail
11.25.2 Bioassay Technology Laboratory Business Overview
11.25.3 Bioassay Technology Laboratory Anti-CD133 Antibody Introduction
11.25.4 Bioassay Technology Laboratory Revenue in Anti-CD133 Antibody Business (2019-2024)
11.25.5 Bioassay Technology Laboratory Recent Development
11.26 AAT Bioquest
11.26.1 AAT Bioquest Company Detail
11.26.2 AAT Bioquest Business Overview
11.26.3 AAT Bioquest Anti-CD133 Antibody Introduction
11.26.4 AAT Bioquest Revenue in Anti-CD133 Antibody Business (2019-2024)
11.26.5 AAT Bioquest Recent Development
11.27 Sino Biological
11.27.1 Sino Biological Company Detail
11.27.2 Sino Biological Business Overview
11.27.3 Sino Biological Anti-CD133 Antibody Introduction
11.27.4 Sino Biological Revenue in Anti-CD133 Antibody Business (2019-2024)
11.27.5 Sino Biological Recent Development
11.28 ProteoGenix
11.28.1 ProteoGenix Company Detail
11.28.2 ProteoGenix Business Overview
11.28.3 ProteoGenix Anti-CD133 Antibody Introduction
11.28.4 ProteoGenix Revenue in Anti-CD133 Antibody Business (2019-2024)
11.28.5 ProteoGenix Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock